Tri Locum Partners LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001826434

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 19 positions · Total reported value $813.22M · Top-10 concentration 80.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 57.1% · 4 new · 6 cut · 2 exited

Active Share (vs S&P 500): 97.2% · vs QQQ: 98.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +9.3% · vs SPY -5.5% · Prev Value $712.55M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Tri Locum Partners LP disclosed 19 equity positions with a combined reported value of $813.22M. The filing implies a focused portfolio: its ten largest positions account for 80.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were JNJ ($107.92M), VRTX ($100.24M), LLY ($91.79M). By sector, the heaviest allocations are Health Care 100.0%. Versus the prior quarter, allocation shifted toward Health Care (+13.6pp) and away from Other (-4.4pp), Industrials (-9.1pp).

Versus the prior quarter, Tri Locum Partners LP opened 4 new positions, trimmed 6 and fully exited 2, a turnover rate of 57.1% of positions. The portfolio's overlap with the prior quarter was 71% of names.

The largest new positions opened in Q2 2026 were ELVN ($43.99M), RVMD ($28.43M), CYTK ($16.53M).

Of the 2 positions fully exited versus the prior quarter, the largest were TMO ($65.08M), NUVL ($31.61M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ELVN ENLIVEN THERAPEUTICS INC · $43.99M
  • RVMD REVOLUTION MEDICINES INC COM · $28.43M
  • CYTK CYTOKINETICS INC · $16.53M
  • BBNX BETA BIONICS INC · $7.73M

Fully Exited (vs previous quarter)

  • TMO THERMO FISHER · prev qtr: $65.08M
  • NUVL NUVALENT INC · prev qtr: $31.61M

Insider Transactions (Form 4)

Latest Tri Locum Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Tri Locum Partners LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 19 positions worth $813.22M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-119074 (status: Approved), registered 2020-07-16
  • Regulatory AUM (Form ADV): $1.09B as of 2026-04-06
  • Client mix (by RAUM): pension and profit-sharing plans 64%, sovereign wealth funds 36%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 19 positions · $813.22M reported value (Q2 2026)
  • Top 10 holdings = 80.0% of reported value
  • Largest position: JNJ (JOHNSON & JOHNSON) at 13.3%
  • Average position size: $42.80M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 new, 9 added, 6 reduced, 2 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The Tri Locum Partners LP fund appears to be taking a bullish stance on the healthcare sector, particularly biotech and pharmaceutical companies, with a significant increase in positions across these sectors. 2. Key Moves: - Added: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND), Dexcom (DXCM), Axsome Therapeutics (AXSM), Jazz Pharmaceuticals (JAZZ), Enlivene Therapeutics (ELVN), Argenx (ARGX). These additions reflect a focus on growth and innovation in the healthcare space. - Reduced: Madrigal Pharmaceuticals (MDGL). This reduction suggests a possible shift away from mid-cap biotech companies or a reassessment of the company's potential. 3. Portfolio Structure: - Passive/Active: The fund seems to be active, as it is making strategic changes to its holdings. - Sector Bias: Strong bias towards the healthcare sector, particularly biotech and pharmaceuticals. - Risk Appetite: The addition of high-growth biotech companies indicates a higher risk appetite. 4. Per-Holding One-Liner: - JNJ: Johnson & Johnson is a diversified healthcare company with a focus on consumer health, pharmaceuticals, and medical devices. - VRTX: Vertex Pharmaceuticals is a biotechnology company specializing in the development of therapies for rare diseases. - LLY: Eli Lilly & Co. is a pharmaceutical company known for its insulin products and a broad range of prescription drugs. - ASND: Ascendis Pharma is a biopharmaceutical company focused on developing therapies for rare genetic disorders. - DXCM: Dexcom is a medical device company specializing in continuous glucose monitoring systems for diabetes management. - AXSM: Axsome Therapeutics is a biopharmaceutical company focused on the development of treatments for central nervous system disorders. - JAZZ: Jazz Pharmaceuticals is a biopharmaceutical company known for its treatments for neurological and psychiatric conditions. - ELVN: Enlivene Therapeutics is a biotechnology company developing therapies for cancer. - ARGX: Argenx is a biotechnology company focused on the development of therapies for rare and autoimmune diseases. - MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development of therapies for metabolic diseases. 5. One-Sentence Style Summary: Tri Locum Partners LP is actively reallocating its portfolio towards high-growth biotech and pharmaceutical companies, reflecting a bullish outlook on the healthcare sector.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 424.94K $107.92M 13.27%
13.27%
Add
2 201.79K $100.24M 12.33%
12.33%
Add
3 76.53K $91.79M 11.29%
11.29%
Add
4 258.74K $69.01M 8.49%
8.49%
Add
5 820.48K $55.26M 6.79%
6.79%
Add
6 219.31K $53.68M 6.60%
6.60%
Add
7 221.72K $53.43M 6.57%
6.57%
Add
8 866.72K $43.99M 5.41%
5.41%
New
9 41.60K $38.59M 4.75%
4.75%
Add
10 68.27K $36.66M 4.51%
4.51%
Reduce
11 151.82K $28.43M 3.50%
3.50%
New
12 47.03K $25.48M 3.13%
3.13%
Reduce
13 746.84K $25.30M 3.11%
3.11%
Reduce
14 328.34K $20.67M 2.54%
2.54%
Add
15 47.98K $19.08M 2.35%
2.35%
Reduce
16 194.00K $16.53M 2.03%
2.03%
New
17 120.71K $11.77M 1.45%
1.45%
Reduce
18 493.34K $7.73M 0.95%
0.95%
New
19 163.00K $7.67M 0.94%
0.94%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)

Low-confidence forecast This fund replaces about 52% of its Top-10 each quarter and backtests at F1 49% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 49% · recall 49% · F1 49% · avg rank error 4.1 · Top-10 turnover 52%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 30% 30% 30% ABBV · TEVA · KVUE · GEHC · REGN · ASND · BIIB · CTLT · AVDL · XENE TEVA · AVDL · SILK · NTRA · ASND · LEGN · MRK · VRTX · MDGL · BAX
2024-Q2 40% 40% 40% TEVA · SILK · AVDL · LEGN · ASND · NTRA · MDGL · MRK · VRTX · BAX TEVA · ARGX · ASND · AMGN · NTRA · AXSM · INSM · MRUS · REGN · MDGL
2024-Q3 40% 40% 40% TEVA · ARGX · ASND · AXSM · NTRA · AMGN · INSM · MDGL · MRUS · INSP PFE · TEVA · NTRA · STVN · ARGX · INSP · PCVX · AVDL · UTHR · LEGN
2024-Q4 70% 70% 70% PFE · TEVA · NTRA · STVN · ARGX · INSP · PCVX · AVDL · UTHR · VRNA TEVA · ZBH · ARGX · NTRA · INSP · STVN · AXSM · VRNA · AVDL · BMY
2025-Q1 40% 40% 40% TEVA · ZBH · ARGX · NTRA · INSP · STVN · AXSM · VRNA · AVDL · NVO CI · MCK · SLNO · TEVA · INSP · MDGL · AXSM · ARGX · GILD · ILMN
2025-Q2 60% 60% 60% CI · MCK · SLNO · TEVA · AXSM · MDGL · INSP · GILD · ARGX · ILMN TEVA · MDGL · ALNY · ARGX · ASND · SLNO · VRNA · INSP · UNH · AXSM
2025-Q3 50% 50% 50% TEVA · MDGL · ALNY · ARGX · ASND · SLNO · UNH · INSP · VRNA · AXSM JNJ · UTHR · MRK · AXSM · ASND · VERA · ARGX · MDGL · SLNO · ABBV
2025-Q4 50% 50% 50% UTHR · JNJ · MRK · AXSM · ASND · VERA · ARGX · MDGL · SLNO · ABBV JNJ · DHR · LLY · UTHR · ASND · MDGL · BSX · TEVA · IONS · VERA
2026-Q1 50% 50% 50% JNJ · DHR · LLY · UTHR · ASND · MDGL · BSX · TEVA · VERA · IONS JNJ · ISRG · TMO · ASND · VRTX · LLY · MDGL · DXCM · UTHR · NUVL
2026-Q2 ★ 60% 60% 60% JNJ · ISRG · TMO · ASND · VRTX · MDGL · LLY · DXCM · UTHR · NUVL JNJ · VRTX · LLY · ASND · DXCM · AXSM · JAZZ · ELVN · ARGX · MDGL

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Tri Locum Partners LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Tri Locum Partners LP reported 19 equity positions worth $813.22M in aggregate; its largest disclosed positions were JNJ ($107.92M), VRTX ($100.24M), LLY ($91.79M).

How large is Tri Locum Partners LP's portfolio?

Tri Locum Partners LP reported $813.22M of long equity holdings across 19 positions as of 2026-Q2. Top-10 holdings account for 80.0% of reported value.

What is Tri Locum Partners LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/tri-locum-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →